• Reported GAAP EPS of $0.57 down -44.66% YoY • Reported revenue of $360.9M up 12.15% YoY • LivaNova PLC expects full-year 2026 revenue to grow 6.0% to 7.0% on a constant-currency basis. Adjusted diluted earnings per share is projected between $4.15 and $4.25, with adjusted free cash flow in the $160 million to $180 million range.
Bullish
LivaNova PLC secured increased VNS Therapy reimbursement and FDA approval for its digital health platform. The company also achieved double-digit reported and organic revenue growth with continued operating margin expansion for full-year 2025.
Bearish
LivaNova PLC faced a full-year 2025 U.S. GAAP diluted loss per share of $4.45 due to a $365.6M environmental liability. The company also experienced a significant Q4 GAAP EPS decline and a substantial decrease in Other Revenue.